

Proof of concept for rabbit based MemoMAB process

February 29 2016 - MEMO has reached proof of concept with its *rb*MemoMAB™ process. First monoclonal antibody candidates could be isolated from an immunized rabbit. This milestone also triggered the the release of the next tranche of Series A financing round.

About Memo Therapeutics AG

Memo Therapeutics is an innovator in the area of recombinant immunoglobulins and human-derived monoclonal antibodies. The technological core of Memo Therapeutics is MemoMAB™ – a technology enabling cost and time-effective molecular cloning and expression of the complete antibody repertoire of one or several human subjects.

Memo Therapeutics capitalizes on the MemoMAB™ platform by developing proprietary technologies and products and by offering services in the area of recombinant immunoglobulins and monoclonal antibodies.